Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05801497
Other study ID # FIBROTHERM
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2023
Est. completion date June 2025

Study information

Verified date April 2023
Source University of Siena
Contact Antonella Fioravanti
Phone +390577233345
Email fioravanti7@virgilio.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Balneotherapy (BT) is recommended as non-pharmacological treatment for Fibromyalgia Syndrome (FS). BT efficacy is based on beneficial properties of both mud bath and stay in a spa environment. The main aim of this multicentric prospective longitudinal cohort study is to evaluate BT effectiveness in patients withFS. All FS patients with a stable treatment in the past month and a Fibromyalgia Impact Questionnaire (FIQ) score ≥39 will be enrolled after providing written informed consent. Patients will be divided into two groups based on whether or not BT is added to usual therapy: BT Group and Control Group. Each patients will be assessed at baseline, after 15 and 45 days in BT Group and at baseline and after 15 days in Control group with an assessment of pain by Visual Analogue Scale, FIQ, Short-Form Health Survey, State-Trait Anxiety Inventory (STAI) and Center for Epidemiologic Studies Depression Scale (CES-D). Collected data will provide a new insight of BT role and the removal of daily stress in FS management


Recruitment information / eligibility

Status Recruiting
Enrollment 520
Est. completion date June 2025
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of primary FS according to the 2010 American College of Rheumatology (ACR) criteria; - Pharmacological and non pharmacological treatment stable for at least 3 months; - FIQ-Total score = 39 Exclusion Criteria: - Secondary FS; - Primary FS patients actually enrolled in other clinical trials; - Patients who had receveid a cycle of BT or of mud-bath in the previous 6 months; - Patients treated with intra-articular steroid injections of any joints in the previous 3 months; - Pregnancy or breastfeeding; - Cognitive or psychiatric disorders and history of substance abuse; - Absolute and relative contraindications to BT

Study Design


Intervention

Procedure:
Balneotherapy
The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks. The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica.

Locations

Country Name City State
Italy Azienda Ospedaliera Universitaria Senese Siena

Sponsors (2)

Lead Sponsor Collaborator
University of Siena Azienda Ospedaliera Universitaria Senese

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Minimal Clinically Important Difference (MCID) Percentage of patients achieving MCDI, defined as a reduction>14% of FIQ-total score 15 days
Secondary Visual Analogue Scale (VAS) Assessment of pain on a 0-10-cm Visual Analogue Scale (VAS) with 0 = "no pain" and 10 = "the worst pain possible" basal time;15 days;45 days
Secondary Fibromyalgia Impact Questionnaire (FIQ) FIQ is an extensively validated patient self-report questionnaire, evaluating the impact of FS on daily life. In this study, we will use the Italian version of the FIQ. It ranges from 0 to 100, with higher scores indicating greater impact of FS on functioning. basal time;15 days;45 days
Secondary Short-Form Health Survey (SF-12) The 12-item SF-12 is a short version of SF-36 that is a widely used measure of health and well-being, validated in multiple countries, including Italy. SF-12 comprises two main domains: the physical component score (PCS) and the mental component score (MCS), and eight scales for assessing eight dimensions: physical functioning, physical role, social role, emotional role, bodily pain, general health, vitality, and mental health. Scores range from "0 to 100" where "0" indicates the worst condition and "100" indicates the best possible condition. basal time;15 days;45 days
Secondary State-Trait Anxiety Inventory (STAI) STAI is a self-report questionnaire with two independent 20-item scales (STAI T-Anxiety Scale or Form X-2 and STAI S-Anxiety Scale or Form X-1) for measuring state-related or trait-related anxiety. A high score on the STAI corresponds to a high level of anxiety symptoms. We will use the Italian validated version. basal time;15 days;45 days
Secondary Center for Epidemiologic Studies Depression Scale (CES-D) The 20-item CES-D Scale is frequently used to estimate the prevalence of depressive symptomatology in the general population. Respondents rate the frequency with which they have experienced particular depressive symptoms during the past week. Responses to each item range from 0 (less than 1 day) to 3 (5-7 days) and are summed to compute a total score. The Italian version measures one depression factor scoring from 0 to 60; scores of 16 or above are considered cases of depression. basal time;15 days;45 days
Secondary Adverse events Percentage of patients reporting adverse events 15 days
See also
  Status Clinical Trial Phase
Completed NCT03149198 - Mat Pilates Method in the Treatment of Women With Fibromyalgia N/A
Completed NCT00965081 - A Study for Adult Patients With Fibromyalgia Phase 4
Enrolling by invitation NCT06100926 - Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain N/A
Recruiting NCT05068791 - Psilocybin-facilitated Treatment for Chronic Pain Early Phase 1
Active, not recruiting NCT04422522 - Fibromyalgia During the COVID-19 Pandemic
Completed NCT05361577 - Exopulse Mollii Suit and Fibromyalgia N/A
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting NCT05941780 - Pain Phenotypes in Patients With Fibromyalgia Syndrome
Not yet recruiting NCT06424743 - Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training N/A
Completed NCT04771260 - Understanding Health Services Delivery for Fibromyalgia
Active, not recruiting NCT04690400 - Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic N/A
Recruiting NCT05644054 - The Impact of THC on Pain Modulation in Fibromyalgia N/A
Enrolling by invitation NCT04098757 - Fibromyalgia Different Approaches: Acupuncture vs Migratens
Completed NCT01697254 - The CARRA Registry N/A
Completed NCT00678691 - An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Phase 4
Recruiting NCT04832100 - Bio-significance of LPC16:0 in Fibromyalgia
Not yet recruiting NCT05688787 - Efficacy of Perineural Injection Therapy in Primary Fibromyalgia N/A
Completed NCT03905486 - Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia. N/A